Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 624-630, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (59)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duffy, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duffy, M. J.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2001;47:624-630.)
© 2001 American Association for Clinical Chemistry, Inc.

Articles

Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?

Michael J. Duffy1

1 Department of Nuclear Medicine, St Vincent’s University Hospital, Dublin 4, and Department of Surgery and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland.

Background: Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers worldwide. Its main application is mostly in gastrointestinal cancers, especially in colorectal malignancy. Although in use for almost 30 years, the clinical value of CEA in colorectal cancer is still not clear.

Methods: The literature relevant to the clinical value of CEA in colorectal cancer was reviewed. Particular attention was paid to studies involving metaanalyses and guidelines issued by Expert Panels.

Results: Although of little use in detecting early colorectal cancer, high preoperative concentrations of CEA correlate with adverse prognosis. Serial CEA measurements can detect recurrent colorectal cancer with a sensitivity of ~80%, a specificity of ~70%, and can provide a lead time of ~5 months. CEA is the most frequent indicator of recurrence in asymptomatic patients and currently is the most cost-effective test for the preclinical detection of resectable disease. CEA is most useful for the early detection of liver metastasis in patients with diagnosed colorectal cancer. Overall, however, little evidence is available that monitoring of all patients with diagnosed colorectal cancer leads to enhanced patient outcome or quality of life.

Conclusions: Currently, the most useful application of CEA is in the detection of liver metastasis from colorectal cancers. Because of the relative success of surgery in resecting hepatic metastases, serial determinations of the marker are recommended for detecting cancer spread to the liver. In the future, preoperative concentrations of CEA may be included with the standard staging procedures for assessing prognosis.




The following articles in journals at HighWire Press have cited this article:


Home page
 Ann. Surg. Oncol.Home page
Y. Toiyama, C. Miki, Y. Inoue, Y. Okugawa, Y. Koike, T. Yokoe, K. Tanaka, and M. Kusunoki
Soluble Intercellular Adhesion Molecule-1 as a Prognostic Marker for Stage II Colorectal Cancer Patients
Ann. Surg. Oncol., June 1, 2008; 15(6): 1617 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H. Korner, K. Soreide, P. J. Stokkeland, and J. A. Soreide
Diagnostic Accuracy of Serum-Carcinoembryonic Antigen in Recurrent Colorectal Cancer: A Receiver Operating Characteristic Curve Analysis
Ann. Surg. Oncol., February 1, 2007; 14(2): 417 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Wallner, A. Herbst, A. Behrens, A. Crispin, P. Stieber, B. Goke, R. Lamerz, and F. T. Kolligs
Methylation of Serum DNA Is an Independent Prognostic Marker in Colorectal Cancer
Clin. Cancer Res., December 15, 2006; 12(24): 7347 - 7352.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
M. Roessler, W. Rollinger, L. Mantovani-Endl, M.-L. Hagmann, S. Palme, P. Berndt, A. M. Engel, M. Pfeffer, J. Karl, H. Bodenmuller, et al.
Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-based Approach for Data Analysis
Mol. Cell. Proteomics, November 1, 2006; 5(11): 2092 - 2101.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Umetani, J. Kim, S. Hiramatsu, H. A. Reber, O. J. Hines, A. J. Bilchik, and D. S. B. Hoon
Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU Repeats.
Clin. Chem., June 1, 2006; 52(6): 1062 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. J. Duffy
Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
Clin. Chem., March 1, 2006; 52(3): 345 - 351.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K S Nair, R Naidoo, and R Chetty
Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value
J. Clin. Pathol., April 1, 2005; 58(4): 343 - 351.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

CEA should be measured in all colorectalcancer patients participating in clinical trials.
Joseph WATINE
Clinical Chemistry Online, 27 Apr 2001 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.